Heart Valve Disease: When Repair Is Better Than Replacement

Cardiac Surgery · 4 · March 8, 2026

If your cardiologist tells you that you need heart valve surgery, the first question shouldn't be "when?" It should be "can it be repaired instead of replaced?" That distinction changes your recovery, your medication burden, and potentially your lifespan. And the answer depends heavily on which valve, what's wrong with it, and who does the surgery.

Mitral Valve: Repair Should Be the Default

The mitral valve sits between the left atrium and left ventricle. When it leaks (regurgitation), blood flows backward into the atrium, causing the heart to work harder. Over time, this leads to heart failure.

For degenerative mitral regurgitation — the most common type, caused by floppy leaflets or ruptured chordae — repair is strongly preferred over replacement. The evidence is unambiguous. A 2024 analysis of the STS Adult Cardiac Surgery Database covering 67,000 mitral valve operations found that repair was associated with 40% lower operative mortality than replacement (0.8% vs 3.4%) and better 10-year survival (78% vs 62%).

Repair avoids the need for lifelong anticoagulation (required with mechanical replacement valves) and preserves the natural valve apparatus, which helps maintain left ventricular function. The American College of Cardiology guidelines give mitral valve repair a Class I recommendation when performed at centers with expertise.

The Surgeon Matters — A Lot

Here's the uncomfortable truth: not all cardiac surgeons are equally skilled at mitral valve repair. Repair is technically demanding. The surgeon reconstructs the valve using techniques like triangular or quadrangular resection, artificial chordae implantation, and annuloplasty ring placement. A surgeon who does 25+ mitral repairs per year will have repair rates above 95% for degenerative disease. A surgeon who does 5 per year might replace half of them because repair is harder.

The Society of Thoracic Surgeons publishes outcome data. Before agreeing to mitral valve surgery, ask your surgeon two questions: What is your repair rate for degenerative mitral valve disease? And how many have you done in the past year? If the answer to the first question is below 90%, consider a second opinion.

Aortic Valve: Replacement Dominates, But Options Have Expanded

The aortic valve is different. When it develops stenosis (narrowing), the leaflets calcify and stiffen. Unlike the mitral valve, aortic valve repair for stenosis is rarely feasible — the valve needs to be replaced. The choice is between a mechanical valve (lasts 20+ years but requires lifelong warfarin) and a bioprosthetic valve (no blood thinners needed but wears out in 10-15 years).

For patients over 65, bioprosthetic valves are generally recommended because the valve is likely to outlast the patient, and avoiding warfarin reduces bleeding risk. For younger patients (under 50), the calculus is harder — do you want lifelong blood thinners or a reoperation in 10-15 years?

TAVR: The Catheter-Based Revolution

Transcatheter aortic valve replacement (TAVR) has transformed treatment for aortic stenosis. Instead of open-heart surgery, a compressed valve is delivered through a catheter (usually via the femoral artery) and deployed inside the diseased native valve. The PARTNER 3 trial showed that TAVR was noninferior to surgery even in low-risk patients, with faster recovery and shorter hospital stays.

TAVR is now performed in patients across all risk categories. But it has limitations. Valve durability beyond 10 years is still being studied. Paravalvular leaks (small gaps around the replacement valve) are more common than with surgical replacement. And for patients under 65, most guidelines still recommend surgical replacement because the long-term data for TAVR in young patients simply doesn't exist yet.

Tricuspid Valve: The Forgotten Valve Getting Attention

The tricuspid valve has been called the "forgotten valve" because it was traditionally ignored unless disease was severe. That's changing. Significant tricuspid regurgitation affects outcomes in heart failure, AFib, and post-left-sided valve surgery. New transcatheter devices (TriClip, EVOQUE) are being used to repair the tricuspid valve without open surgery. The TRILUMINATE trial showed the TriClip device reduced tricuspid regurgitation by at least one grade in 87% of patients. This is an evolving field with rapid progress.

Key Takeaways

- Mitral valve repair has 40% lower operative mortality than replacement and better 10-year survival — always ask if repair is possible

- Surgeon volume matters enormously: high-volume mitral repair surgeons (25+/year) achieve 95%+ repair rates

- TAVR is now available for aortic stenosis across all risk categories, but long-term durability data beyond 10 years is limited

- Mechanical valves last 20+ years but require lifelong warfarin; bioprosthetic valves avoid blood thinners but wear out in 10-15 years

- Tricuspid valve disease is finally getting effective catheter-based treatments — ask about transcatheter options

Comparing heart valve surgery options and costs across countries? Use our global cardiac surgery cost comparison tool.